OTTAWA, Oct. 3, 2016 /CNW/ -áMany Canadians are struggling with opioid misuse and need access to better treatment. When Canadianssuffer overdoses, the impacts are felt in families and communities, and the Government of Canada is committed to taking measures to help fight the effects of this growing problem.
Today, the Honourable Jane Philpott,
Naloxone can save lives when used promptly, by temporarily reversing a potentially fatal opioid overdose, and the nasal spray is considered to be easier to use than the injectable version, particularly by those who are not healthcare professionals.
With federal market authorization, the manufacturer is now able to take the necessary steps to bring the Canadian naloxone nasal spray to market. In the meantime, the Interim Order will remain in effect and the US-approved product will continue to be available in Canada, to avoid any interruption in supply.
"Canada is facing a growing number of opioid overdoses and deaths occurring across the country. This crisis demands that we take action now, and I'm proud to see my department working with its neighbours in the United States, and expediting approvals here in Canada, to provide Canadians with much-needed treatment options." Jane PhilpottMinister of Health
Health Canada Allowing Immediate Access to Nasal Naloxone announcement July 2016 Health Canada Statement on Change to Prescription Drug List for NaloxoneáHealth Canada's Action on Opioid Misuse
Interim OrderIndustry Notice on Change to Prescription Drug List for Naloxone
Health Canada news releases are available on the Internet at: www.healthcanada.gc.ca/media
SOURCE Health Canada
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All